Patents by Inventor Shane Donovan

Shane Donovan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fibrin gel for controlled release of PDGF and uses thereof
    Patent number: 9012393
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: April 21, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • Fibrin gel for controlled release of PDGF and uses thereof
    Patent number: 8377864
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Grant
    Filed: June 19, 2008
    Date of Patent: February 19, 2013
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • BIOMATRICES TO ATTRACT AND RETAIN REGENERATIVE AND REPARATIVE CELLS
    Publication number: 20110200577
    Abstract: The invention relates to a pharmaceutical composition which comprises a fibrin clot and a cytokine and methods of delivering the composition to a site of disease or injury in vivo to attract and retain regenerative or reparative stem or myeloid cells and their differentiated progeny.
    Type: Application
    Filed: January 10, 2011
    Publication date: August 18, 2011
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Stephen L. Smith, Loredana Campo, Jennifer Campbell, Shiri Uriel Wallach, Wanda Seyton, Shane Donovan
  • Method of the invention preparations of factor IXa
    Patent number: 7767647
    Abstract: The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides an improved method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity, thus reducing the incidence of undesired side effects in a subject.
    Type: Grant
    Filed: July 30, 2008
    Date of Patent: August 3, 2010
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Shane Donovan, Donald Baker
  • FIBRIN GEL FOR CONTROLLED RELEASE OF PDGF AND USES THEREOF
    Publication number: 20090075881
    Abstract: The present invention relates, in general, to fibrin sealants, which contain platelet derived growth factor (PDGF) for controlled release in situ for therapeutic applications, including musculoskeletal disorders, soft tissue disorders and vascular diseases.
    Type: Application
    Filed: June 19, 2008
    Publication date: March 19, 2009
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Isabelle Catelas, Joseph Dwyer, Wanda Seyton, Shane Donovan, Sam L. Helgerson
  • Factor IXa for the treatment of bleeding disorders
    Publication number: 20090069543
    Abstract: The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides an improved method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity, thus reducing the incidence of undesired side effects in a subject.
    Type: Application
    Filed: July 30, 2008
    Publication date: March 12, 2009
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA
    Inventors: Shane Donovan, Donald Baker
  • Factor IXa for the treatment of bleeding disorders
    Patent number: 7425539
    Abstract: The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides an improved method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity, thus reducing the incidence of undesired side effects in a subject.
    Type: Grant
    Filed: February 28, 2005
    Date of Patent: September 16, 2008
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Shane Donovan, Donald A. Baker
  • Factor IXa for the treatment of bleeding disorders
    Publication number: 20050209149
    Abstract: The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides an improved method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity, thus reducing the incidence of undesired side effects in a subject.
    Type: Application
    Filed: February 28, 2005
    Publication date: September 22, 2005
    Inventors: Shane Donovan, Donald Baker